Prognosis and treatment outcomes for patients with stage IA triple-negative breast cancer

To evaluate the role of chemotherapy in stage IA triple-negative breast cancer, we conducted a retrospective population-based study including 8601 patients. The use of chemotherapy significantly increased from 2010 to 2019 in patients with T1b and T1c tumors ( p  = 0.001 and p  

Saved in:
Bibliographic Details
Published in:NPJ breast cancer 2024-04, Vol.10 (1), p.26-26, Article 26
Main Authors: Tarantino, Paolo, Leone, Julieta, Vallejo, Carlos T., Freedman, Rachel A., Waks, Adrienne G., Martínez-Sáez, Olga, Garrido-Castro, Ana, Lynce, Filipa, Tayob, Nabihah, Lin, Nancy U., Tolaney, Sara M., Leone, Jose P.
Format: Article
Language:English
Subjects:
692/4028/67/1347
692/699/67/1347
Biomedical and Life Sciences
Biomedicine
Breast cancer
Brief Communication
Cancer Research
Cancer therapies
Cell Biology
Chemotherapy
Clinical outcomes
Histology
Human Genetics
Marital status
Mastectomy
Medical prognosis
Medical research
Metropolitan areas
Oncology
Patients
Population-based studies
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c485t-38261f1159a6cadc4c9b3e103391a272b945b00f611966c7038b35c307c947ab3
cites cdi_FETCH-LOGICAL-c485t-38261f1159a6cadc4c9b3e103391a272b945b00f611966c7038b35c307c947ab3
container_end_page 26
container_issue 1
container_start_page 26
container_title NPJ breast cancer
container_volume 10
creator Tarantino, Paolo
Leone, Julieta
Vallejo, Carlos T.
Freedman, Rachel A.
Waks, Adrienne G.
Martínez-Sáez, Olga
Garrido-Castro, Ana
Lynce, Filipa
Tayob, Nabihah
Lin, Nancy U.
Tolaney, Sara M.
Leone, Jose P.
description To evaluate the role of chemotherapy in stage IA triple-negative breast cancer, we conducted a retrospective population-based study including 8601 patients. The use of chemotherapy significantly increased from 2010 to 2019 in patients with T1b and T1c tumors ( p  = 0.001 and p  
doi_str_mv 10.1038/s41523-024-00634-6
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_1fa3677d68434dd1aa72422112ac6937</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_1fa3677d68434dd1aa72422112ac6937</doaj_id><sourcerecordid>3032863055</sourcerecordid><originalsourceid>FETCH-LOGICAL-c485t-38261f1159a6cadc4c9b3e103391a272b945b00f611966c7038b35c307c947ab3</originalsourceid><addsrcrecordid>eNp9kc1u1TAQhS1ERavSF-gCWWLDJsX2-CdZVhXQK1WCBV10ZU0cJ-QqiS-2Q8Xb4zalIBZ4Y2vmm2MfH0LOObvgDOr3SXIloGJCVoxpkJV-QU4EGFlJbczLv87H5CylPWOMS103ir8ix1Aro3TDT8jdlxiGJaQxUVw6mqPHPPsl07BmF2afaB8iPWAeSzHR-zF_oynj4OnustDjYfLV4ofS_-FpW6ZTpg4X5-NrctTjlPzZ035Kbj9--Hp1Xd18_rS7urypnKxVrqAWmvecqwa1w85J17Tgi0VoOAoj2kaqlrFec95o7Uzx3oJywIxrpMEWTslu0-0C7u0hjjPGnzbgaB8LIQ4WYx7d5C3vEcqHdLqWILuOIxohheBcoNMNmKL1btM6xPB99SnbeUzOTxMuPqzJAgMpZFmioG__QfdhjUtx-kCJWgNTqlBio1wMKUXfPz-QM_uQo91ytCVH-5ij1WXozZP02s6-ex75nVoBYANSaS2Dj3_u_o_sL7j-pbE</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3032863055</pqid></control><display><type>article</type><title>Prognosis and treatment outcomes for patients with stage IA triple-negative breast cancer</title><source>Publicly Available Content Database</source><source>PubMed Central</source><source>Springer Nature - nature.com Journals - Fully Open Access</source><creator>Tarantino, Paolo ; Leone, Julieta ; Vallejo, Carlos T. ; Freedman, Rachel A. ; Waks, Adrienne G. ; Martínez-Sáez, Olga ; Garrido-Castro, Ana ; Lynce, Filipa ; Tayob, Nabihah ; Lin, Nancy U. ; Tolaney, Sara M. ; Leone, Jose P.</creator><creatorcontrib>Tarantino, Paolo ; Leone, Julieta ; Vallejo, Carlos T. ; Freedman, Rachel A. ; Waks, Adrienne G. ; Martínez-Sáez, Olga ; Garrido-Castro, Ana ; Lynce, Filipa ; Tayob, Nabihah ; Lin, Nancy U. ; Tolaney, Sara M. ; Leone, Jose P.</creatorcontrib><description>To evaluate the role of chemotherapy in stage IA triple-negative breast cancer, we conducted a retrospective population-based study including 8601 patients. The use of chemotherapy significantly increased from 2010 to 2019 in patients with T1b and T1c tumors ( p  = 0.001 and p  &lt; 0.001, respectively). Receipt of chemotherapy was associated with improved breast cancer-specific survival (BCSS, adjusted hazard ratio = 0.70; p  = 0.006), particularly in patients with T1c tumors (5-year BCSS 94.5% vs. 91.2%).</description><identifier>ISSN: 2374-4677</identifier><identifier>EISSN: 2374-4677</identifier><identifier>DOI: 10.1038/s41523-024-00634-6</identifier><identifier>PMID: 38575691</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>692/4028/67/1347 ; 692/699/67/1347 ; Biomedical and Life Sciences ; Biomedicine ; Breast cancer ; Brief Communication ; Cancer Research ; Cancer therapies ; Cell Biology ; Chemotherapy ; Clinical outcomes ; Histology ; Human Genetics ; Marital status ; Mastectomy ; Medical prognosis ; Medical research ; Metropolitan areas ; Oncology ; Patients ; Population-based studies ; Tumors</subject><ispartof>NPJ breast cancer, 2024-04, Vol.10 (1), p.26-26, Article 26</ispartof><rights>The Author(s) 2024</rights><rights>2024. The Author(s).</rights><rights>The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c485t-38261f1159a6cadc4c9b3e103391a272b945b00f611966c7038b35c307c947ab3</citedby><cites>FETCH-LOGICAL-c485t-38261f1159a6cadc4c9b3e103391a272b945b00f611966c7038b35c307c947ab3</cites><orcidid>0000-0001-8686-0228 ; 0000-0002-5940-8671 ; 0000-0002-8537-652X ; 0000-0002-5989-6636 ; 0000-0001-6615-7076</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/3032863055/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/3032863055?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>314,778,782,25736,27907,27908,36995,36996,44573,74877</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38575691$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tarantino, Paolo</creatorcontrib><creatorcontrib>Leone, Julieta</creatorcontrib><creatorcontrib>Vallejo, Carlos T.</creatorcontrib><creatorcontrib>Freedman, Rachel A.</creatorcontrib><creatorcontrib>Waks, Adrienne G.</creatorcontrib><creatorcontrib>Martínez-Sáez, Olga</creatorcontrib><creatorcontrib>Garrido-Castro, Ana</creatorcontrib><creatorcontrib>Lynce, Filipa</creatorcontrib><creatorcontrib>Tayob, Nabihah</creatorcontrib><creatorcontrib>Lin, Nancy U.</creatorcontrib><creatorcontrib>Tolaney, Sara M.</creatorcontrib><creatorcontrib>Leone, Jose P.</creatorcontrib><title>Prognosis and treatment outcomes for patients with stage IA triple-negative breast cancer</title><title>NPJ breast cancer</title><addtitle>npj Breast Cancer</addtitle><addtitle>NPJ Breast Cancer</addtitle><description>To evaluate the role of chemotherapy in stage IA triple-negative breast cancer, we conducted a retrospective population-based study including 8601 patients. The use of chemotherapy significantly increased from 2010 to 2019 in patients with T1b and T1c tumors ( p  = 0.001 and p  &lt; 0.001, respectively). Receipt of chemotherapy was associated with improved breast cancer-specific survival (BCSS, adjusted hazard ratio = 0.70; p  = 0.006), particularly in patients with T1c tumors (5-year BCSS 94.5% vs. 91.2%).</description><subject>692/4028/67/1347</subject><subject>692/699/67/1347</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Breast cancer</subject><subject>Brief Communication</subject><subject>Cancer Research</subject><subject>Cancer therapies</subject><subject>Cell Biology</subject><subject>Chemotherapy</subject><subject>Clinical outcomes</subject><subject>Histology</subject><subject>Human Genetics</subject><subject>Marital status</subject><subject>Mastectomy</subject><subject>Medical prognosis</subject><subject>Medical research</subject><subject>Metropolitan areas</subject><subject>Oncology</subject><subject>Patients</subject><subject>Population-based studies</subject><subject>Tumors</subject><issn>2374-4677</issn><issn>2374-4677</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNp9kc1u1TAQhS1ERavSF-gCWWLDJsX2-CdZVhXQK1WCBV10ZU0cJ-QqiS-2Q8Xb4zalIBZ4Y2vmm2MfH0LOObvgDOr3SXIloGJCVoxpkJV-QU4EGFlJbczLv87H5CylPWOMS103ir8ix1Aro3TDT8jdlxiGJaQxUVw6mqPHPPsl07BmF2afaB8iPWAeSzHR-zF_oynj4OnustDjYfLV4ofS_-FpW6ZTpg4X5-NrctTjlPzZ035Kbj9--Hp1Xd18_rS7urypnKxVrqAWmvecqwa1w85J17Tgi0VoOAoj2kaqlrFec95o7Uzx3oJywIxrpMEWTslu0-0C7u0hjjPGnzbgaB8LIQ4WYx7d5C3vEcqHdLqWILuOIxohheBcoNMNmKL1btM6xPB99SnbeUzOTxMuPqzJAgMpZFmioG__QfdhjUtx-kCJWgNTqlBio1wMKUXfPz-QM_uQo91ytCVH-5ij1WXozZP02s6-ex75nVoBYANSaS2Dj3_u_o_sL7j-pbE</recordid><startdate>20240404</startdate><enddate>20240404</enddate><creator>Tarantino, Paolo</creator><creator>Leone, Julieta</creator><creator>Vallejo, Carlos T.</creator><creator>Freedman, Rachel A.</creator><creator>Waks, Adrienne G.</creator><creator>Martínez-Sáez, Olga</creator><creator>Garrido-Castro, Ana</creator><creator>Lynce, Filipa</creator><creator>Tayob, Nabihah</creator><creator>Lin, Nancy U.</creator><creator>Tolaney, Sara M.</creator><creator>Leone, Jose P.</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><general>Nature Portfolio</general><scope>C6C</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-8686-0228</orcidid><orcidid>https://orcid.org/0000-0002-5940-8671</orcidid><orcidid>https://orcid.org/0000-0002-8537-652X</orcidid><orcidid>https://orcid.org/0000-0002-5989-6636</orcidid><orcidid>https://orcid.org/0000-0001-6615-7076</orcidid></search><sort><creationdate>20240404</creationdate><title>Prognosis and treatment outcomes for patients with stage IA triple-negative breast cancer</title><author>Tarantino, Paolo ; Leone, Julieta ; Vallejo, Carlos T. ; Freedman, Rachel A. ; Waks, Adrienne G. ; Martínez-Sáez, Olga ; Garrido-Castro, Ana ; Lynce, Filipa ; Tayob, Nabihah ; Lin, Nancy U. ; Tolaney, Sara M. ; Leone, Jose P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c485t-38261f1159a6cadc4c9b3e103391a272b945b00f611966c7038b35c307c947ab3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>692/4028/67/1347</topic><topic>692/699/67/1347</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Breast cancer</topic><topic>Brief Communication</topic><topic>Cancer Research</topic><topic>Cancer therapies</topic><topic>Cell Biology</topic><topic>Chemotherapy</topic><topic>Clinical outcomes</topic><topic>Histology</topic><topic>Human Genetics</topic><topic>Marital status</topic><topic>Mastectomy</topic><topic>Medical prognosis</topic><topic>Medical research</topic><topic>Metropolitan areas</topic><topic>Oncology</topic><topic>Patients</topic><topic>Population-based studies</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tarantino, Paolo</creatorcontrib><creatorcontrib>Leone, Julieta</creatorcontrib><creatorcontrib>Vallejo, Carlos T.</creatorcontrib><creatorcontrib>Freedman, Rachel A.</creatorcontrib><creatorcontrib>Waks, Adrienne G.</creatorcontrib><creatorcontrib>Martínez-Sáez, Olga</creatorcontrib><creatorcontrib>Garrido-Castro, Ana</creatorcontrib><creatorcontrib>Lynce, Filipa</creatorcontrib><creatorcontrib>Tayob, Nabihah</creatorcontrib><creatorcontrib>Lin, Nancy U.</creatorcontrib><creatorcontrib>Tolaney, Sara M.</creatorcontrib><creatorcontrib>Leone, Jose P.</creatorcontrib><collection>Springer Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>NPJ breast cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tarantino, Paolo</au><au>Leone, Julieta</au><au>Vallejo, Carlos T.</au><au>Freedman, Rachel A.</au><au>Waks, Adrienne G.</au><au>Martínez-Sáez, Olga</au><au>Garrido-Castro, Ana</au><au>Lynce, Filipa</au><au>Tayob, Nabihah</au><au>Lin, Nancy U.</au><au>Tolaney, Sara M.</au><au>Leone, Jose P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognosis and treatment outcomes for patients with stage IA triple-negative breast cancer</atitle><jtitle>NPJ breast cancer</jtitle><stitle>npj Breast Cancer</stitle><addtitle>NPJ Breast Cancer</addtitle><date>2024-04-04</date><risdate>2024</risdate><volume>10</volume><issue>1</issue><spage>26</spage><epage>26</epage><pages>26-26</pages><artnum>26</artnum><issn>2374-4677</issn><eissn>2374-4677</eissn><abstract>To evaluate the role of chemotherapy in stage IA triple-negative breast cancer, we conducted a retrospective population-based study including 8601 patients. The use of chemotherapy significantly increased from 2010 to 2019 in patients with T1b and T1c tumors ( p  = 0.001 and p  &lt; 0.001, respectively). Receipt of chemotherapy was associated with improved breast cancer-specific survival (BCSS, adjusted hazard ratio = 0.70; p  = 0.006), particularly in patients with T1c tumors (5-year BCSS 94.5% vs. 91.2%).</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>38575691</pmid><doi>10.1038/s41523-024-00634-6</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0001-8686-0228</orcidid><orcidid>https://orcid.org/0000-0002-5940-8671</orcidid><orcidid>https://orcid.org/0000-0002-8537-652X</orcidid><orcidid>https://orcid.org/0000-0002-5989-6636</orcidid><orcidid>https://orcid.org/0000-0001-6615-7076</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2374-4677
ispartof NPJ breast cancer, 2024-04, Vol.10 (1), p.26-26, Article 26
issn 2374-4677
2374-4677
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_1fa3677d68434dd1aa72422112ac6937
source Publicly Available Content Database; PubMed Central; Springer Nature - nature.com Journals - Fully Open Access
subjects 692/4028/67/1347
692/699/67/1347
Biomedical and Life Sciences
Biomedicine
Breast cancer
Brief Communication
Cancer Research
Cancer therapies
Cell Biology
Chemotherapy
Clinical outcomes
Histology
Human Genetics
Marital status
Mastectomy
Medical prognosis
Medical research
Metropolitan areas
Oncology
Patients
Population-based studies
Tumors
title Prognosis and treatment outcomes for patients with stage IA triple-negative breast cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T17%3A33%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognosis%20and%20treatment%20outcomes%20for%20patients%20with%20stage%20IA%20triple-negative%20breast%20cancer&rft.jtitle=NPJ%20breast%20cancer&rft.au=Tarantino,%20Paolo&rft.date=2024-04-04&rft.volume=10&rft.issue=1&rft.spage=26&rft.epage=26&rft.pages=26-26&rft.artnum=26&rft.issn=2374-4677&rft.eissn=2374-4677&rft_id=info:doi/10.1038/s41523-024-00634-6&rft_dat=%3Cproquest_doaj_%3E3032863055%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c485t-38261f1159a6cadc4c9b3e103391a272b945b00f611966c7038b35c307c947ab3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3032863055&rft_id=info:pmid/38575691&rfr_iscdi=true